{"id":"NCT04400058","sponsor":"Octapharma","briefTitle":"Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression","officialTitle":"Efficacy and Safety of Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-06-01","primaryCompletion":"2022-02-01","completion":"2022-02-01","firstPosted":"2020-05-22","resultsPosted":"2024-01-18","lastUpdate":"2024-01-18"},"enrollment":207,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Covid-19"],"interventions":[{"type":"BIOLOGICAL","name":"Octagam 10%","otherNames":[]},{"type":"OTHER","name":"Saline Solution","otherNames":[]}],"arms":[{"label":"Octagam 10%","type":"EXPERIMENTAL"},{"label":"Saline Solution","type":"PLACEBO_COMPARATOR"}],"summary":"This is a randomized, double-blind, placebo-controlled, multicenter, Phase 3 study to evaluate if high-dose Octagam 10% therapy can stabilize or improve clinical status in patients with severe Coronavirus disease","primaryOutcome":{"measure":"Proportion of Subjects Reaching Stabilization or Improvement in Clinical Status at Day 7","timeFrame":"7 days","effectByArm":[{"arm":"Octagam 10%","deltaMin":89,"sd":null},{"arm":"Placebo","deltaMin":82,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":22,"countries":["United States","Russia","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":105},"commonTop":["Constipation","Headache","Diarrhoea","Anxiety","Insomnia"]}}